93. Primary biliary cholangitis Clinical trials / Disease details


Clinical trials : 282 Drugs : 245 - (DrugBank : 56) / Drug target genes : 35 - Drug target pathways : 113

  
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-002965-67-NL
(EUCTR)
07/07/201729/03/2017A study on the effect of obetihcolic acid on bile composition in patients with PBC (chronic liver disease of the small bile ducts), NASH (chronic liver disease as a result of fatty liver) and healthy volunteersAn open, non-randomized, parallel-group pharmokinetic and -dynamic, investigator-initiated study on effects of obeticholic acid (OCA) in bile of patients with primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) in comparison to healthy controls - OCABILE Primary biliairy cholangitis (PBC)Non-alcoholic steatohepatitis (NASH)
MedDRA version: 20.0;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
AMCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Netherlands
2EUCTR2011-004728-36-NL
(EUCTR)
01/06/201215/02/2012A study of Obeticholic Acid versus Placebo in Patients with Primary Biliary Cirrhosis plus long term extension study only with Obeticholic Acid A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis Primary biliary cirrhosis
MedDRA version: 18.0;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Intercept Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes
180 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noSweden;United Kingdom;Italy;Netherlands;Germany;Australia;Austria;Belgium;Spain;Poland;Canada;United States
3EUCTR2011-004728-36-PL
(EUCTR)
30/05/201220/04/2012A Phase 3, Double Blind, Placebo Controlled Trial and Long Term SafetyExtension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis A Phase 3, Double Blind, Placebo Controlled Trial and Long Term SafetyExtension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis Primary biliary cirrhosis
MedDRA version: 20.0;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Intercept Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Spain;Austria;Switzerland;United Kingdom;Italy;Canada;Poland;Belgium;Australia;Netherlands;Germany;Sweden
4EUCTR2011-004728-36-SE
(EUCTR)
16/04/201216/02/2012A study of Obeticholic Acid versus Placebo in Patients with Primary Biliary Cirrhosis plus long term extension study only with Obeticholic AcidA Phase 3, Double Blind, Placebo Controlled Trial and Long Term SafetyExtension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis Primary biliary cirrhosis
MedDRA version: 20.0;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Intercept Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Canada;Poland;Spain;Belgium;Austria;Australia;Germany;Netherlands;Italy;United Kingdom;Sweden
5EUCTR2011-004728-36-BE
(EUCTR)
30/03/201213/02/2012A study of Obeticholic Acid versus Placebo in Patients with Primary Biliary Cirrhosis plus long term extension study only with Obeticholic AcidA Phase 3, Double Blind, Placebo Controlled Trial and Long Term SafetyExtension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis Primary biliary cirrhosis
MedDRA version: 20.0;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Intercept Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Canada;Poland;Spain;Belgium;Austria;Australia;Germany;Netherlands;Italy;United Kingdom;Sweden
6EUCTR2011-004728-36-DE
(EUCTR)
22/03/201216/02/2012A study of Obeticholic Acid versus Placebo in Patients with Primary Biliary Cirrhosis plus long term extension study only with Obeticholic AcidA Phase 3, Double Blind, Placebo Controlled Trial and Long Term SafetyExtension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis Primary biliary cirrhosis
MedDRA version: 20.0;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Intercept Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Canada;Poland;Spain;Belgium;Austria;Australia;Netherlands;Germany;Italy;United Kingdom;Sweden
7EUCTR2011-004728-36-AT
(EUCTR)
13/03/201220/02/2012A study of Obeticholic Acid versus Placebo in Patients with Primary Biliary Cirrhosis plus long term extension study only with Obeticholic Acid A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis Primary biliary cirrhosis
MedDRA version: 20.0;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Intercept Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes
180 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited States;Canada;Poland;Spain;Belgium;Australia;Austria;Germany;Netherlands;Italy;United Kingdom;Sweden
8EUCTR2011-004728-36-IT
(EUCTR)
13/03/201205/03/2012A study of Obeticholic Acid versus Placebo in Patients with Primary Biliary Cirrhosis plus long term extension study only with Obeticholic AcidA Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis - A study of OCA in Patients with Primary Biliary Cirrhosis Primary biliary cirrhosis
MedDRA version: 14.1;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Acido Obeticolico
Other descriptive name: Obeticholic Acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Acido Obeticolico
Other descriptive name: Obeticholic Acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Acido Obeticolico
Other descriptive name: Obeticholic Acid
INTERCEPT PHARMACEUTICALS, INC.NULLNot Recruiting Female: yes
Male: yes
180 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited States;Canada;Poland;Spain;Belgium;Austria;Germany;Netherlands;United Kingdom;Italy;Sweden
9EUCTR2011-004728-36-GB
(EUCTR)
09/03/201223/02/2012A study of Obeticholic Acid versus Placebo in Patients with Primary Biliary Cirrhosis plus long term extension study only with Obeticholic AcidA Phase 3, Double Blind, Placebo Controlled Trial and Long Term SafetyExtension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis Primary biliary cirrhosis
MedDRA version: 20.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Trade Name: Ocaliva
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Intercept Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Canada;Poland;Spain;Belgium;Austria;Australia;Germany;Netherlands;Italy;United Kingdom;Sweden
10EUCTR2011-004728-36-ES
(EUCTR)
22/02/201222/02/2012A study of Obeticholic Acid versus Placebo in Patients with Primary Biliary Cirrhosis plus long term extension study only with Obeticholic Acid A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis Primary biliary cirrhosis
MedDRA version: 14.1;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Obeticholic acid
Intercept Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes
150 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited States;Spain;Austria;Switzerland;United Kingdom;Italy;France;Canada;Poland;Belgium;Germany;Netherlands;Sweden